Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5% – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price fell 5% during trading on Monday . The stock traded as low as $4.55 and last traded at $4.56. 47,927 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 1,351,573 shares. The stock had previously closed at $4.80.

Autolus Therapeutics Stock Performance

The business has a 50 day moving average price of $3.97 and a 200 day moving average price of $4.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market capitalization of $1.18 billion, a PE ratio of -3.70 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, equities research analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AUTL. Renaissance Technologies LLC increased its holdings in shares of Autolus Therapeutics by 253.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock worth $3,985,000 after purchasing an additional 821,156 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares during the last quarter. Millennium Management LLC raised its position in Autolus Therapeutics by 113.7% in the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after buying an additional 432,503 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after acquiring an additional 111,131 shares during the period. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after acquiring an additional 925,000 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.